Type 2 diabetes
Conditions
Interventions
Sponsors
State Key Laboratory of Subhealth Intervention Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients who met all of the following criteria were eligible for the trial: 1. Patients aged 18-75 years (including 18 and 75 years old) at the time of screening were not limited to men and women; 2. Patients with type 2 diabetes who meet the diagnostic criteria for diabetes issued by the World Health Organization in 1999 and are taking diabetes drugs; 3. Patients with body mass index (BMI) of 18.0-35.0 kg / m2 (including both ends) at screening; 4. Patients who are willing and able to accurately use home blood glucose meter for self blood glucose monitoring; 5. Patients with type 2 diabetes who have an urgent desire to improve their physical condition and fully understand the "cmnt" theory, 6. Patients who can understand and abide by the trial process voluntarily participate in the trial and provide informed consent.
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes, diabetes mellitus or secondary diabetes due to pancreatic injury (such as Cushing's syndrome or acromegaly); 2. Have used other drugs that may affect blood glucose metabolism in recent two months, including systemic glucocorticoids (except inhaled or topical), growth hormones, etc.; 3. Antihypertensive drugs or blood lipid regulating drugs were used, but the dose before screening did not reach a stable state; 4. A history or condition of any of the following heart problems within the last 6 months; 5. Decompensated cardiac insufficiency (NYHA grade III or IV); 6. Unstable angina pectoris, myocardial infarction, coronary artery bypass grafting or stent implantation history; 7. Uncontrolled or severe arrhythmias (such as long QT syndrome, etc.) that have been evaluated by the investigator as inappropriate to participate in this clinical trial; 8. Had hemorrhagic stroke or ischemic stroke in the last 6 months and was ineligible to participate in this clinical trial as assessed by the investigator; 9. Suffering from cerebral thrombosis, cerebral vascular blockage, cerebral hemangioma, mini-stroke, cerebral hemorrhage, cerebral stroke, cerebral infarction, cerebral infarction, hydrocephalus, brain tumor (malignant) and other diseases; 10. Patients who meet any of the following criteria will not be allowed to participate in this trial: 11. Type 1 diabetes, diabetes mellitus or secondary diabetes due to pancreatic injury (such as Cushing's syndrome or acromegaly); 12. Have used other drugs that may affect blood glucose metabolism in recent two months, including systemic glucocorticoids (except inhaled or topical), growth hormones, etc.; 13. Antihypertensive drugs or blood lipid regulating drugs were used, but the dose before screening did not reach a stable state; 14. A history or condition of any of the following heart problems within the last 6 months:; 15. Decompensated cardiac insufficiency (NYHA grade III or IV); 16. Unstable angina pectoris, myocardial infarction, coronary artery bypass grafting or stent implantation history 17. Uncontrolled or severe arrhythmias (such as long QT syndrome, etc.) that have been evaluated by the investigator as inappropriate to participate in this clinical trial; 18. Had hemorrhagic stroke or ischemic stroke in the last 6 months and was ineligible to participate in this clinical trial as assessed by the investigator; 19. Suffering from cerebral thrombosis, cerebral vascular blockage, cerebral hemangioma, mini-stroke, cerebral hemorrhage, cerebral stroke, cerebral infarction, cerebral infarction, hydrocephalus, brain tumor (malignant) and other diseases; 20. History of carotid artery stent implantation; 21. System with nephrotic syndrome, uremia, polycystic kidney, kidney transplantation, lateral kidney removal/congenital single kidney, renal atrophy, renal tumor; 22. Digestive system with liver ascites, liver cirrhosis, liver flukes, severe hepatitis, varicose gastric fundus; 23. The nervous system has cerebellar atrophy, demyelination, cerebral palsy, Parkinson's disease, mania, schizophrenia; 24. Pulmonary embolism and pulmonary heart disease in respiratory system; 25. In the aspect of motor system, he had artery rupture and myeloma; 26. Immune system with Bezier's disease, lupus erythematosus eruption; 27. Having chondrosarcoma, liposarcoma, brucellosis, leukemia; 28. A history of malignancy within the last 5 years or is currently being assessed for potenti
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| withdraw rate of antidiabetic medicine; | — |
Secondary
| Measure | Time frame |
|---|---|
| glycated haemoglobin;Fasting blood glucose;2-hour postprandial blood glucose;Body mass index;Blood pressure;Quality of life;Treatment satisfaction; | — |
Countries
China
Contacts
Public ContactDongbo Liu
State Key Laboratory of Subhealth Intervention Technology
Outcome results
None listed